{
  "id": 1855281,
  "title": "Hadassah performs first-ever alpha radiation treatment for recurring brain tumors",
  "url": "https://urgent.news/2026/08/19/hadassah-performs-first-ever-alpha-radiation-treatment-for-recurring",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-19T03:32:50.000Z",
  "source": {
    "name": "Jerusalem Post",
    "slug": "jerusalem-post",
    "url": "https://www.jpost.com/health-and-wellness/article-905948"
  },
  "original_language": "en",
  "account": "At Hadassah Medical Center in Jerusalem, a groundbreaking alpha radiation treatment for recurring brain tumors has been successfully performed for the very first time in the world. The innovative Alpha DaRT technology, developed in collaboration with the Sharett Institute of Oncology and ALPHA Tau, utilizes highly bioefficient alpha particles to target tumors with minimal damage to surrounding brain tissue.\n\nThe 77-year-old patient, diagnosed with a glioblastoma recurrence after previous treatments, became Israel's inaugural recipient of the Alpha DaRT therapy. This pioneering procedure involved injecting radiation sources from two pathways simultaneously, enabling optimal tumor coverage while maintaining exceptional accuracy.\n\nProfessor Yigal Shoshan, Director of Neurosurgery, Oncology, and Stereotactic Radiosurgery Unit at Hadassah, led the surgery alongside a multidisciplinary team from various departments. The results have garnered interest in the neuro-oncology community, as preliminary findings were published in the US. The technology's seamless integration with existing neurosurgical navigation systems further enhances its appeal.\n\nHadassah's Director of the Sharett Institute of Oncology, Professor Aron Popovtzer, emphasized the significance of glioblastoma being the most common primary malignant brain tumor in adults, with almost all patients experiencing recurrence despite standard treatments. The limited treatment options for recurrent disease underscore the importance of innovative therapies like Alpha DaRT.\n\nAlpha Tau CEO Uzi Sofer hailed the treatment as a significant milestone for the company, emphasizing that the technology born in Israel will benefit Israeli patients. The study aims to examine the feasibility and safety of the treatment, with future plans to expand the clinical program to encompass targeted brain metastases.",
  "summary": "The technology, which emits highly bioefficient alpha particles that deliver concentrated radiation, was developed in collaboration with the Sharett Institute of Oncology and ALPHA Tau.",
  "key_points": [
    "Hadassah Medical Center performs first-ever alpha radiation treatment for brain tumors.",
    "77-year-old patient with glioblastoma recurrence becomes Israel's inaugural recipient.",
    "Alpha DaRT technology developed in collaboration with Sharett Institute of Oncology and ALPHA Tau."
  ],
  "editors_take": "This pioneering treatment signals a potential shift in managing recurring brain tumors, offering new hope for patients with limited options, and positions Hadassah and Alpha Tau at the forefront of neuro-oncology innovation.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}